Avillion’s co-development model draws Pfizer into first deal
By Nuala Moran
Thursday, January 16, 2014
LONDON – After a year of spreading the word and working to convince people of the attractions of its finance and risk-sharing model, Avillion Group Partners LLP has signed up Pfizer Inc. as the first partner for its Phase III co-development scheme.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.